Original Article
Phosphorylated retinoblastoma is a biomarker of overall disease control and better progression-free survival of recurrent epithelial ovarian cancer patients treated with second-line topoisomerase inhibitor CPT-11 chemotherapy
Abstract
Background: To determine the association of phosphorylated retinoblastoma (p-RB) with the clinical outcome of recurrent epithelial ovarian cancer (EOC) patients after CPT-11 chemotherapy.
Methods: We enrolled 27 recurrent EOC patients who had failed first-line chemotherapy and underwent second-line and above CPT-11 chemotherapy from January 2002 to September 2016 in our hospital. The complete medical records of the patients were retrospectively reviewed. The phosphorylation of RB at Ser780 (p-RB) in surgical tumors and 27 normal ovarian tissues was assessed by immunohistochemistry.
Results: The positive rate of p-RB expression in EOC tissues was significantly higher than that in normal ovarian tissues (62.96% vs. 22.22%, P<0.05). p-RB expression had no obvious relationship with the patient’s lymph node metastasis, platinum sensitivity, Federation of Gynecology and Obstetrics (FIGO) stage, histological grade, initial symptoms of ascites, pathological type, age, neoadjuvant chemotherapy, or type of first-line chemotherapy (all P>0.05). In addition, p-RB expression was significantly associated with disease control rates of CPT-11 chemotherapy (P<0.001). Univariate analysis showed that p-RB expression, FIGO stage, lymph node metastasis, and initial symptoms of ascites were factors affecting progression-free survival (PFS) after CPT-11 chemotherapy in recurrent EOC patients (all P<0.05). Multivariate analysis showed that p-RB expression was an independent prognostic factor for PFS in the recurrent EOC patients who accepted CPT-11 chemotherapy (P<0.05).
Conclusions: The positive rate of p-RB expression in EOC tissues was significantly higher than that in normal ovarian tissues, and p-RB expression was significantly correlated with disease control rates and PFS of recurrent EOC patients after CPT-11 chemotherapy. Our findings suggest that p-RB is a prognostic biomarker for recurrent EOC patients who accept CPT-11 therapy after first-line chemotherapy failure.
Methods: We enrolled 27 recurrent EOC patients who had failed first-line chemotherapy and underwent second-line and above CPT-11 chemotherapy from January 2002 to September 2016 in our hospital. The complete medical records of the patients were retrospectively reviewed. The phosphorylation of RB at Ser780 (p-RB) in surgical tumors and 27 normal ovarian tissues was assessed by immunohistochemistry.
Results: The positive rate of p-RB expression in EOC tissues was significantly higher than that in normal ovarian tissues (62.96% vs. 22.22%, P<0.05). p-RB expression had no obvious relationship with the patient’s lymph node metastasis, platinum sensitivity, Federation of Gynecology and Obstetrics (FIGO) stage, histological grade, initial symptoms of ascites, pathological type, age, neoadjuvant chemotherapy, or type of first-line chemotherapy (all P>0.05). In addition, p-RB expression was significantly associated with disease control rates of CPT-11 chemotherapy (P<0.001). Univariate analysis showed that p-RB expression, FIGO stage, lymph node metastasis, and initial symptoms of ascites were factors affecting progression-free survival (PFS) after CPT-11 chemotherapy in recurrent EOC patients (all P<0.05). Multivariate analysis showed that p-RB expression was an independent prognostic factor for PFS in the recurrent EOC patients who accepted CPT-11 chemotherapy (P<0.05).
Conclusions: The positive rate of p-RB expression in EOC tissues was significantly higher than that in normal ovarian tissues, and p-RB expression was significantly correlated with disease control rates and PFS of recurrent EOC patients after CPT-11 chemotherapy. Our findings suggest that p-RB is a prognostic biomarker for recurrent EOC patients who accept CPT-11 therapy after first-line chemotherapy failure.
